Daily Stock Analysis, ABEO, Abeona Therapeutics Inc, priceseries

Abeona Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
13.95
Close
14.00
High
14.05
Low
13.55
Previous Close
13.80
Daily Price Gain
0.20
YTD High
22.00
YTD High Date
Apr 23, 2018
YTD Low
10.50
YTD Low Date
Feb 15, 2018
YTD Price Change
-3.20
YTD Gain
-18.60%
52 Week High
22.75
52 Week High Date
Oct 11, 2017
52 Week Low
10.50
52 Week Low Date
Feb 15, 2018
52 Week Price Change
-2.20
52 Week Gain
-13.58%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 19. 2017
5.05
May 3. 2017
5.32
10 Trading Days
5.25%
Link
LONG
Jun 21. 2017
5.00
Jul 25. 2017
8.91
23 Trading Days
78.11%
Link
LONG
Aug 23. 2017
8.75
Sep 22. 2017
14.96
21 Trading Days
71.01%
Link
LONG
Oct 10. 2017
19.95
Oct 11. 2017
21.35
1 Trading Days
7.02%
Link
LONG
Feb 6. 2018
15.95
Feb 8. 2018
17.42
2 Trading Days
9.25%
Link
LONG
Mar 1. 2018
14.00
Mar 13. 2018
15.10
8 Trading Days
7.89%
Link
LONG
Apr 9. 2018
16.55
Apr 24. 2018
18.69
11 Trading Days
12.93%
Link
Company Information
Stock Symbol
ABEO
Exchange
NasdaqCM
Company URL
http://www.abeonatherapeutics.com
Company Phone
2149055100
CEO
Timothy J. Miller
Headquarters
Texas
Business Address
3333 LEE PARKWAY, SUITE 600, DALLAS, TX 75219
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000318306
About

Abeona Therapeutics, Inc. operates as an emerging pharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer and supportive care of cancer patients. It focuses on developing a range of pharmaceutical and medical device products primarily based upon nanopolymer chemistry technologies and other drug delivery technologies. The company's products are ProctiGard, LexaGard, CobOral and CobaCyte. Abeona Therapeutics was founded in 1974 and is headquartered in Dallas, TX.

Description

Abeona Therapeutics Inc., a biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company offers MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis. Its lead program is an adeno-associated virus (AAV)-based gene therapy for sanfilippo syndrome. The company develops ABO-101 for Mucopolysaccharidosis (MPS) III, a sanfilippo syndrome Type B; ABO-102 for MPS III, a sanfilippo syndrome Type A; ABO-201 for juvenile batten disease; ABO-301 for fanconi anemia; and clustered, regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 AAV for rare blood diseases. It also develops PTB-101 salt diafiltration process (SDF) Alpha, a alpha1-proteinase inhibitor for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe deficiency of alpha1-proteinase inhibitor; and PTB-102 SDF IVIG, an intravenous immunoglobulin for autoimmune, infectious, and idiopathic diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.